Is adiponectin a bystander or a mediator in heart failure? the tangled thread of a good-natured adipokine in aging and cardiovascular disease

Ken Shinmura

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Adiponectin is an adipose tissue-derived adipokine abundant in human plasma. Increasing evidence from experimental studies suggests that adiponectin plays a protective role in the cardiovascular system. However, epidemiological studies revealed that high levels of adiponectin were associated with increased mortality and severity of congestive heart failure. Furthermore, several prospective studies indicated that high levels of adiponectin were positively correlated with increased total and cardiovascular disease mortality in the elderly. These results are completely opposite to our expectation based on the beneficial effects of adiponectin. Clinical observations demonstrated that plasma adiponectin levels were positively associated with B-type natriuretic peptide levels. Clinical and experimental studies indicated that the administration of atrial natriuretic peptide enhanced adiponectin production. It is still controversial whether increased adiponectin production is a bystander or a key mediator in the development of heart failure. However, recent investigations strongly suggest that increased adiponectin production in patients with heart failure is a part of compensatory mechanisms against oxidative stress and inflammation. In addition, complicated "adiponectin resistance" will accelerate a counter-regulatory increase in adiponectin in patients with advanced heart failure, although direct evidence that patients with heart failure have "adiponectin resistance" is still lacking. Increased adiponectin production might contribute, at least in part, to the metabolic and structural remodeling of the failing heart via activation of AMP-activated protein kinase and induction of cyclooxygenase-2. Further investigation is needed to clarify the exact role of increased adiponectin production under pathophysiological conditions.

Original languageEnglish
Pages (from-to)457-466
Number of pages10
JournalHeart Failure Reviews
Volume15
Issue number5
DOIs
Publication statusPublished - 2010 Sep

Fingerprint

Adipokines
Adiponectin
Cardiovascular Diseases
Heart Failure
AMP-Activated Protein Kinases
Mortality
Brain Natriuretic Peptide
Atrial Natriuretic Factor
Cyclooxygenase 2
Cardiovascular System
Adipose Tissue
Epidemiologic Studies

Keywords

  • Adiponectin
  • AMP-activated protein kinase
  • Cardiovascular disease
  • Elderly
  • Heart failure
  • Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Is adiponectin a bystander or a mediator in heart failure? the tangled thread of a good-natured adipokine in aging and cardiovascular disease. / Shinmura, Ken.

In: Heart Failure Reviews, Vol. 15, No. 5, 09.2010, p. 457-466.

Research output: Contribution to journalArticle

@article{b1864e5a974f4789bae589d00bf14c46,
title = "Is adiponectin a bystander or a mediator in heart failure? the tangled thread of a good-natured adipokine in aging and cardiovascular disease",
abstract = "Adiponectin is an adipose tissue-derived adipokine abundant in human plasma. Increasing evidence from experimental studies suggests that adiponectin plays a protective role in the cardiovascular system. However, epidemiological studies revealed that high levels of adiponectin were associated with increased mortality and severity of congestive heart failure. Furthermore, several prospective studies indicated that high levels of adiponectin were positively correlated with increased total and cardiovascular disease mortality in the elderly. These results are completely opposite to our expectation based on the beneficial effects of adiponectin. Clinical observations demonstrated that plasma adiponectin levels were positively associated with B-type natriuretic peptide levels. Clinical and experimental studies indicated that the administration of atrial natriuretic peptide enhanced adiponectin production. It is still controversial whether increased adiponectin production is a bystander or a key mediator in the development of heart failure. However, recent investigations strongly suggest that increased adiponectin production in patients with heart failure is a part of compensatory mechanisms against oxidative stress and inflammation. In addition, complicated {"}adiponectin resistance{"} will accelerate a counter-regulatory increase in adiponectin in patients with advanced heart failure, although direct evidence that patients with heart failure have {"}adiponectin resistance{"} is still lacking. Increased adiponectin production might contribute, at least in part, to the metabolic and structural remodeling of the failing heart via activation of AMP-activated protein kinase and induction of cyclooxygenase-2. Further investigation is needed to clarify the exact role of increased adiponectin production under pathophysiological conditions.",
keywords = "Adiponectin, AMP-activated protein kinase, Cardiovascular disease, Elderly, Heart failure, Mortality",
author = "Ken Shinmura",
year = "2010",
month = "9",
doi = "10.1007/s10741-010-9159-5",
language = "English",
volume = "15",
pages = "457--466",
journal = "Heart Failure Reviews",
issn = "1382-4147",
publisher = "Springer Netherlands",
number = "5",

}

TY - JOUR

T1 - Is adiponectin a bystander or a mediator in heart failure? the tangled thread of a good-natured adipokine in aging and cardiovascular disease

AU - Shinmura, Ken

PY - 2010/9

Y1 - 2010/9

N2 - Adiponectin is an adipose tissue-derived adipokine abundant in human plasma. Increasing evidence from experimental studies suggests that adiponectin plays a protective role in the cardiovascular system. However, epidemiological studies revealed that high levels of adiponectin were associated with increased mortality and severity of congestive heart failure. Furthermore, several prospective studies indicated that high levels of adiponectin were positively correlated with increased total and cardiovascular disease mortality in the elderly. These results are completely opposite to our expectation based on the beneficial effects of adiponectin. Clinical observations demonstrated that plasma adiponectin levels were positively associated with B-type natriuretic peptide levels. Clinical and experimental studies indicated that the administration of atrial natriuretic peptide enhanced adiponectin production. It is still controversial whether increased adiponectin production is a bystander or a key mediator in the development of heart failure. However, recent investigations strongly suggest that increased adiponectin production in patients with heart failure is a part of compensatory mechanisms against oxidative stress and inflammation. In addition, complicated "adiponectin resistance" will accelerate a counter-regulatory increase in adiponectin in patients with advanced heart failure, although direct evidence that patients with heart failure have "adiponectin resistance" is still lacking. Increased adiponectin production might contribute, at least in part, to the metabolic and structural remodeling of the failing heart via activation of AMP-activated protein kinase and induction of cyclooxygenase-2. Further investigation is needed to clarify the exact role of increased adiponectin production under pathophysiological conditions.

AB - Adiponectin is an adipose tissue-derived adipokine abundant in human plasma. Increasing evidence from experimental studies suggests that adiponectin plays a protective role in the cardiovascular system. However, epidemiological studies revealed that high levels of adiponectin were associated with increased mortality and severity of congestive heart failure. Furthermore, several prospective studies indicated that high levels of adiponectin were positively correlated with increased total and cardiovascular disease mortality in the elderly. These results are completely opposite to our expectation based on the beneficial effects of adiponectin. Clinical observations demonstrated that plasma adiponectin levels were positively associated with B-type natriuretic peptide levels. Clinical and experimental studies indicated that the administration of atrial natriuretic peptide enhanced adiponectin production. It is still controversial whether increased adiponectin production is a bystander or a key mediator in the development of heart failure. However, recent investigations strongly suggest that increased adiponectin production in patients with heart failure is a part of compensatory mechanisms against oxidative stress and inflammation. In addition, complicated "adiponectin resistance" will accelerate a counter-regulatory increase in adiponectin in patients with advanced heart failure, although direct evidence that patients with heart failure have "adiponectin resistance" is still lacking. Increased adiponectin production might contribute, at least in part, to the metabolic and structural remodeling of the failing heart via activation of AMP-activated protein kinase and induction of cyclooxygenase-2. Further investigation is needed to clarify the exact role of increased adiponectin production under pathophysiological conditions.

KW - Adiponectin

KW - AMP-activated protein kinase

KW - Cardiovascular disease

KW - Elderly

KW - Heart failure

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=77955708292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955708292&partnerID=8YFLogxK

U2 - 10.1007/s10741-010-9159-5

DO - 10.1007/s10741-010-9159-5

M3 - Article

VL - 15

SP - 457

EP - 466

JO - Heart Failure Reviews

JF - Heart Failure Reviews

SN - 1382-4147

IS - 5

ER -